StockData
Bioventus Inc. logo

Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 2, 2026Score 13/3041% below fair value
$10.62+0.02 (+0.19%)

Close on Nov 18, 2026Market cap $893.06MP/E 13.8Yield –

Bioventus free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Bioventus's free cash flow for the twelve months ending Jun 27, 2026 was $94.29M, up 176.5% year over year. For fiscal 2025 it was $72.11M, up 90.8% from the year before. The highest annual figure on record is $72.11M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$72.11M+90.8%
FY2024Dec 31, 2024$37.79M+373.4%
FY2023Dec 31, 2023$7.98M–
FY2022Dec 31, 2022-$15.02M-258.5%
FY2021Dec 31, 2021$9.47M-82.8%
FY2020Dec 31, 2020$55.22M+43.9%
FY2019Dec 31, 2019$38.37M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$18.91M-25.1%
Q1 FY2026Mar 28, 2026$8.36M–
Q4 FY2025Dec 31, 2025$37.39M+99.4%
Q3 FY2025Sep 27, 2025$29.63M+189.0%
Q2 FY2025Jun 28, 2025$25.26M+67.4%
Q1 FY2025Mar 29, 2025-$20.16M–
Q4 FY2024Dec 31, 2024$18.75M+87.4%
Q3 FY2024Sep 28, 2024$10.25M–
Q2 FY2024Jun 29, 2024$15.09M+60.5%
Q1 FY2024Mar 30, 2024-$6.30M–
Q4 FY2023Dec 31, 2023$10.01M-3.8%
Q3 FY2023Sep 30, 2023-$10.35M–
Q2 FY2023Jul 1, 2023$9.40M+933.9%
Q1 FY2023Apr 1, 2023-$1.07M–
Q4 FY2022Dec 31, 2022$10.41M+149.8%
Q3 FY2022Oct 1, 2022-$2.35M-127.1%
Q2 FY2022Jul 2, 2022$909.00K-94.3%
Q1 FY2022Apr 2, 2022-$23.98M–
Q4 FY2021Dec 31, 2021$4.17M-62.8%
Q3 FY2021Oct 2, 2021$8.66M-55.7%
Q2 FY2021Jul 3, 2021$16.06M+127.1%
Q1 FY2021Apr 3, 2021-$19.41M-211.6%
Q4 FY2020Dec 31, 2020$11.20M–
Q3 FY2020Sep 26, 2020$19.56M–
Q2 FY2020Jun 27, 2020$7.07M–
Q1 FY2020Mar 28, 2020$17.39M–

More Bioventus figures

See a number that looks wrong?